Skip to contentpdufa.bio

CAN-3110

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

CAN-3110 is a Candel Therapeutics, Inc. program. Its next catalyst is a Readout in Jan 2027.

CADL catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Candel Therapeutics, Inc. (CADL). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Jan 2027CADL

Specialist biotech funds holding CADL, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RTW Investments3,211,008$33.5 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is CAN-3110's next FDA decision or readout?

The next tracked catalyst for CAN-3110 is a Readout in Jan 2027.

What happened at CAN-3110's most recent FDA decision?

No FDA decision for CAN-3110 is in our archive yet.

Who makes CAN-3110?

Candel Therapeutics, Inc. (CADL).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.